文献速递慢性静脉疾病

InVera输注装置治疗功能不全大隐静脉的12个月初步研究结果

A pilot study of the InVera Infusion Device: Twelve-month outcomes in the treatment of incompetent saphenous veins
RSS 订阅 · PubMed · J Vasc Surg Venous Lymphat Disord · 2026-10-19

单中心前瞻性初步研究纳入10例原发性症状性轴性反流患者,使用InVera输注装置行化学消融。技术成功率100%,无装置相关不良事件,12个月时rVCSS与HASTI评分均较基线显著下降(校正P=0.03),90%患者异常反流消除且完全或部分闭塞。

要点

  • InVera装置技术成功率达100%,随访期内无装置相关不良事件或深静脉血栓。
  • 12个月时rVCSS和HASTI评分均较基线显著降低(校正P=0.03)。
  • 12个月超声显示90%患者异常反流消除且完全或部分闭塞。

核心结论

  • InVera输注装置作为功能不全大隐静脉化学消融的硬化剂输送技术安全有效,12个月解剖、临床及患者报告结局良好。

研究设计与样本

  • 单中心前瞻性初步研究纳入10例原发性症状性轴性反流患者,接受InVera输注装置输送硬化剂的化学消融。

主要发现

  • 技术成功率为100%,随访期间无装置相关不良事件或严重不良事件,包括无深静脉血栓记录。
  • rVCSS和HASTI评分从基线至12个月均显著下降,校正P=0.03。
  • 12个月超声解剖评估显示90%患者异常反流消除且完全或部分闭塞。

关键数值与推荐

  • 技术成功率为100%。
  • 12个月时rVCSS和HASTI评分较基线下降的校正P=0.03。
  • 12个月超声显示90%患者异常反流消除且完全或部分闭塞。

临床怎么用

  • 该装置可作为非热非肿胀(NTNT)化学消融中输送硬化剂的选项,用于功能不全大隐静脉的管理。
  • 术后12个月内可通过rVCSS、HASTI问卷及超声评估临床和解剖结局。

局限性

  • 单中心初步研究样本量仅10例,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

J Vasc Surg Venous Lymphat Disord . 2026 Oct 19:102642. doi: 10.1016/j.jvsv.2026.102642. Online ahead of print. ABSTRACT OBJECTIVE: The InVera Infusion Device is a novel catheter designed for the delivery of sclerosant agents during non-thermal, non-tumescent (NTNT) ablation of incompetent superficial truncal veins of the lower extremity. This device pilot study aimed to evaluate the technical success, safety, and 12-month clinical outcome. METHODS: A single-center, prospective pilot study enrolled 10 patients with primary symptomatic axial reflux who underwent chemical ablation procedures with sclerosant delivery using the InVera Infusion Device. Primary outcomes assessed were technical procedural success, adverse events, Revised Venous Clinical Severity Score (rVCSS), patient-reported outcomes (PROs) based on a HASTI (Heaviness, Achiness, Swelling, Throbbing, Itching) symptom questionnaire and anatomical success rates from duplex ultrasound examination at baseline, 1 week, 8 weeks, 3, 6, and 12 months post procedure. Baseline and 12 months post procedure were compared for both the rVCSS and the HASTI results using a paired t-test and a Wilcoxon signed-rank test respectively RESULTS: Technical procedural success was 100%. There were no device-related adverse events or serious adverse events including no deep vein thrombosis recorded throughout the follow-up period. Clinician assessed rVCSS and patient reported HASTI scores both showed statistically significant reductions from baseline to 12 months (adjusted p = 0.03 for both). Ultrasound-based anatomical assessment at 12 months demonstrated elimination of abnormal reflux and complete or partial occlusion in 90% of patients. CONCLUSIONS: The InVera Infusion device provides a safe and effective technique for the delivery of sclerosant agents as part of the management of incompetent saphenous veins, demonstrating favorable 12-month anatomical, clinical and patient reported outcomes in this pilot cohort. PMID: 42896734 | DOI: 10.1016/j.jvsv.2026.102642

来源:PubMed · J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. PubMed · J Vasc Surg Venous Lymphat Disord:A pilot study of the InVera Infusion Device: Twelve-month outcomes in the treatment of incompetent saphenous veins

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。